Cryoport, Inc. (CYRX) Stock
Key stats
- Market cap
- $860.02M
- Price / Earnings ratio
- -18.8x
- EPS (TTM)
- -$2.91
- Volume
- Loading
- 52-week high
- $18.36
- 52-week low
- $7.61
- Next earnings report
- 3 Nov 2026
Source: third-party data provider, as of October 21, 2026
Compare with CYRX
Recent news

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
CYRX

CryoPort (CYRX) Upgraded to Buy: Here's Why
CryoPort (CYRX) Upgraded to Buy: Here's Why
CYRX

CryoPort Q2 Earnings Call Highlights
CryoPort Q2 Earnings Call Highlights
CYRX

CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CYRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.22
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.20
- MACD histogram
- -0.07
- SMA 50
- $16.53
- Price above SMA 50
- EMA 50
- $16.59
- Price above EMA 50
- SMA 200
- $13.00
- Price above SMA 200
- EMA 200
- $13.34
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 20, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.17 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
CYRX

CryoPort (CYRX) Upgraded to Buy: Here's Why
CryoPort (CYRX) Upgraded to Buy: Here's Why
CYRX

CryoPort Q2 Earnings Call Highlights
CryoPort Q2 Earnings Call Highlights
CYRX

CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CYRX

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CYRX

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
CYRX

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
CYRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Cryoport, Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jerrell W. Shelton | Chairman, President & CEO | 1945 |
| Mr. Robert S. Stefanovich MS | Senior VP, CFO, Treasurer & Chief Administrative Officer | 1965 |
| Mr. Phil Wilson | Chief Operating Officer of Cryoport Systems, LLC | — |
| Mr. Edward J. Zecchini | Senior VP and Chief Digital & Technology Officer | 1962 |
| Dr. Mark W. Sawicki Ph.D. | Senior VP & Chief Scientific Officer | — |
| Mr. Thomas J. Heinzen | Vice President of Corporate Development & Investor Relations | — |
| Mr. Tony Ippolito | VP, General Counsel & Corporate Secretary | — |
| Ms. Kylie A. Crowe | Vice President of Global Human Resources & Organizational Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 21, 2026
Technical indicators
- RSI 14
- 56.22
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.20
- MACD histogram
- -0.07
- SMA 50
- $16.53
- Price above SMA 50
- EMA 50
- $16.59
- Price above EMA 50
- SMA 200
- $13.00
- Price above SMA 200
- EMA 200
- $13.34
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 20, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $19.00
- Average
- $21.33
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.1 | -16.4 | -4.9 | |||||||||
| 2022 | -26.4 | -15.7 | +2.1 | -35.1 | +8.6 | +26.1 | +17.9 | -11.6 | -24.5 | +14.0 | -29.1 | -12.7 |
| 2023 | +31.1 | -3.6 | +8.9 | -9.2 | -13.2 | -5.9 | -7.5 | -10.2 | -3.4 | -26.2 | +47.3 | +4.5 |
| 2024 | -6.1 | +15.9 | -1.2 | -10.7 | -38.8 | -32.8 | +12.2 | |||||
| 2025 | -4.7 | |||||||||||
| 2026 | +0.0 | +51.6 | -1.8 | -4.9 | +3.3 | +11.9 | +0.5 |



